New Carotid Stent Systems Associated With Low Stroke Risk
With complication rates of 1% or less, Neuroguard and CGuard are renewing optimism about CAS, experts said at VIVA 2023.
Source: tctmd.com
📰 Daniel Clair News
Daniel Clair News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Clair. Real-time updates on events, politics, business and more.
PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI
Careful follow-up and good wound care are key to ensuring success in “no-option” patients, says Daniel Clair.
Source: tctmd.com
Vascular InterVentional Advances Conference, VIVA23, Clinical Trial Outcomes: PROMISE II (LimFlow) Trial for TADV, PRELUDE Study (LimbSonic) Therapeutic Ultrasound Presented
Results from five clinical trials were presented during the VIVA (Vascular InterVentional Advances) Conference, VIVA23, providing outcomes from studies on treatment for chronic limb-threatening ischemia (CLTI), use of drug-coated balloons, among other highly-anticipated late-breaking science findings.
Source: dicardiology.com
First Round of Late-Breaking Clinical Trial Results Announced at VIVA23
/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...
Source: prnewswire.com
FDA Approves LimFlow System in Patients with Chronic Limb-threatening Ischemia and No Suitable Endovascular or Surgical Revascularization Options
New therapeutic option has potential to reduce rate of major limb amputation in US
Source: dicardiology.com
Novel System Snags FDA Approval for Severe Peripheral Arterial Disease
Device designed to prevent amputation in chronic limb-threatening ischemia
United States Vanderbilt University Daniel Clair Nicole Lou Vanderbilt University Medical Center Medpage Today
Source: medpagetoday.com
FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI
The basis for the approval was the successful results for deep-vein arterialization borne out in the PROMISE II trial.
Daniel Clair Drug Administration New England Journal Vanderbilt University Medical Center Section Surgical Sciences
Source: tctmd.com
FDA approves LimFlow chronic limb-threatening ischemia treatment
LimFlow announced today that the FDA approved its LimFlow System for treating chronic limb-threatening ischemia (CLTI).
United States Dan Rose Daniel Clair Limflow System Vascular Surgery Vanderbilt University Medical Center Section
Source: massdevice.com
First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023
/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...
Source: prnewswire.com
Transcatheter Arterialization Could Revolutionize Treatment of Limb-Threatening Ischemia
Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.
James Hambrick Mehdi Shishehbor Daniel Clair Amputation University Hospitals Newsroom University Hospitals Harrington Heart Vascular Institute Vanderbilt University
Source: hcplive.com